Australien market open for Augurix

Augurix, a Swiss‐based company active in the development and marketing of in‐vitro medical diagnostics devices devoted to gastroenterology, has already entered into a commercialization agreement for Simtomax with HealthScreenSolutions Pty Ltd, providing HealthScreenSolutions with the exclusive right to distribute and supply Simtomax in Australia and New Zealand.

Celiac Disease detected in 10 minutes with Simtomax
Simtomax is a rapid test for the early screening of celiac disease. Celiac disease, is a widespread gastrointestinal disorder affecting over 250’000 people in Australia, the majority of them being undiagnosed. Thierry Duvanel, CEO of Augurix said: "We are very pleased to have obtained the TGA registration for Simtomax. It opens the doors of the Australian market, a country in which the awareness of Celiac Disease has grown tremendously over the last decade. Simtomax, offers an easy‐to‐use and affordable solution to do early screening of Celiac Disease.”

Distribution in Australia through pharmacies
HealthScreenSolutions will be supplying and supporting the Simtomax®test nationally through the major groups of pharmacies that offer professional health care services. Judy Readman, Marketing Director of HealthScreenSolutions commented: “Pharmacists are now increasingly involved in a range of health care services as well as in Health promotional activities, general health as well as drug‐related advice. Since they are in the front line of primary health care, they provide triage services for a range of community health concerns, frequently referring patients to GP’s or other health professionals.”

About Augurix
Augurix SA is a Swiss‐based company active in the development and marketing of in‐vitro medical diagnostics devices devoted to gastroenterology. Through its portfolio of products, Augurix addresses the medical need of early discrimination between organic and systemic gastrointestinal diseases. Augurix is commercializing a rapid in‐vitro diagnostic test for the early discrimination of Celiac Disease, marketed under the brand Simtomax. Augurix is also developing innovative solutions dedicated to the diagnosis of patients suffering from IBD and other gastro‐intestinal diseases. Augurix was founded in 2007 and has established offices and laboratory premises in Monthey (Valais, Switzerland).